Literature DB >> 3899932

Effects of cyclosporine in experimental cryptococcal meningitis.

J R Perfect, D T Durack.   

Abstract

We studied the effects of cyclosporine on experimental cryptococcal meningitis. Like cortisone, cyclosporine depressed the highly effective defense mechanisms of normal rabbits against inoculated Cryptococcus neoformans, causing them to develop progressive, fatal cryptococcal meningitis. Unlike cortisone, which causes a striking reduction in leukocytes in cerebrospinal fluid, cyclosporine depressed mononuclear cell function rather than numbers. Interleukin 2, a primary target for the immunodepressive action of cyclosporine, appears to be of central importance in central nervous system defenses against cryptococci. The findings suggest that humans receiving cyclosporine are likely to suffer increased incidence of cryptococcal infection.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3899932      PMCID: PMC262129          DOI: 10.1128/iai.50.1.22-26.1985

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Mechanisms of immunosuppression by cyclosporin.

Authors:  P A Keown; G L Essery; C R Stiller; N R Sinclair; R Mullen; R A Ulan
Journal:  Transplant Proc       Date:  1981-03       Impact factor: 1.066

2.  Differential effects of cyclosporin-A on lymphocyte subpopulations.

Authors:  S B Leapman; R S Filo; E J Smith; P G Smith
Journal:  Transplant Proc       Date:  1981-03       Impact factor: 1.066

Review 3.  Cyclosporin-A--present experimental status.

Authors:  J F Borel
Journal:  Transplant Proc       Date:  1981-03       Impact factor: 1.066

4.  Antischistosomal effects of cyclosporin A.

Authors:  E Bueding; J Hawkins; Y N Cha
Journal:  Agents Actions       Date:  1981-07

5.  Response of congenitally athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection.

Authors:  L K Cauley; J W Murphy
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

6.  Immunological and pharmacological monitoring in the clinical use of cyclosporin A.

Authors:  P A Keown; C R Stiller; R A Ulan; N R Sinclair; W J Wall; G Carruthers; W Howson
Journal:  Lancet       Date:  1981-03-28       Impact factor: 79.321

7.  Regulation of cell-mediated immunity in cryptococcosis. I. Induction of specific afferent T suppressor cells by cryptococcal antigen.

Authors:  J W Murphy; J W Moorhead
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

8.  Chronic cryptococcal meningitis: a new experimental model in rabbits.

Authors:  J R Perfect; S D Lang; D T Durack
Journal:  Am J Pathol       Date:  1980-10       Impact factor: 4.307

9.  Induction of specific tolerance in rabbits by kidney allografting and short periods of cyclosporin-A treatment.

Authors:  C J Green; A C Allison; S Precious
Journal:  Lancet       Date:  1979-07-21       Impact factor: 79.321

10.  Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2.

Authors:  D Bunjes; C Hardt; M Röllinghoff; H Wagner
Journal:  Eur J Immunol       Date:  1981-08       Impact factor: 5.532

View more
  18 in total

Review 1.  Antifungal activity of nonantifungal drugs.

Authors:  J Afeltra; P E Verweij
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-06-26       Impact factor: 3.267

2.  Effects of cyclosporin A on the cells responsible for the anticryptococcal cell-mediated immune response and its regulation.

Authors:  P L Fidel; J W Murphy
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

3.  Cyclosporin A modulation of the acute inflammatory response: an explanation for the effect of CsA on host defences in infection.

Authors:  D J Ormrod; S Cawley; T E Miller
Journal:  J Exp Pathol (Oxford)       Date:  1990-02

4.  Opsonic activity of cerebrospinal fluid in experimental cryptococcal meningitis.

Authors:  M M Hobbs; J R Perfect; D L Granger; D T Durack
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.441

5.  Calcineurin is essential for survival during membrane stress in Candida albicans.

Authors:  M Cristina Cruz; Alan L Goldstein; Jill R Blankenship; Maurizio Del Poeta; Dana Davis; Maria E Cardenas; John R Perfect; John H McCusker; Joseph Heitman
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

6.  Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans.

Authors:  M Del Poeta; M C Cruz; M E Cardenas; J R Perfect; J Heitman
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

7.  Cerebrospinal fluid macrophage response to experimental cryptococcal meningitis: relationship between in vivo and in vitro measurements of cytotoxicity.

Authors:  J R Perfect; M M Hobbs; D L Granger; D T Durack
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

8.  The gene encoding phosphoribosylaminoimidazole carboxylase (ADE2) is essential for growth of Cryptococcus neoformans in cerebrospinal fluid.

Authors:  J R Perfect; D L Toffaletti; T H Rude
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

9.  In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus.

Authors:  William J Steinbach; Wiley A Schell; Jill R Blankenship; Chiatogu Onyewu; Joseph Heitman; John R Perfect
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Cyclosporin A inhibits the growth of Cryptococcus neoformans in a murine model.

Authors:  C H Mody; G B Toews; M F Lipscomb
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.